Skip to main content
Premium Trial:

Request an Annual Quote

California Medicaid Program Covering XDx's Heart Transplant Rejection Test

NEW YORK (GenomeWeb News) – California's Medicaid program has begun covering XDx's molecular diagnostic test for heart transplant rejection, the Brisbane, Calif.-based firm announced today.

Medi-Cal has added XDx's test called AlloMap as a new, covered benefit for the monitoring of heart transplants for organ rejection. AlloMap is now covered by more than 200 insurers in the US, and more than 80 percent of tests performed during the past year have been reimbursed, XDx said.

About 2,100 heart transplants are performed each year in the US, XDx noted.

AlloMap measures the expression levels of a set of genes from a blood sample, providing clinicians a tool for evaluating a patient's risk for a transplant rejection. The company launched the test in 2005, and three years later the US Food and Drug Administration approved AlloMap.

"The value of AlloMap consists of its ability to non-invasively determine whether a heart transplant recipient has a low probability of rejection," Mario Deng, medical director of Heart Transplantation at Ronald Reagan UCLA Medical Center, said in a statement. "Utilization of AlloMap can avoid many invasive biopsies, greatly contributing to patients' quality of life."

XDx secured a $15 million senior credit facility in September with plans to develop new applications using its molecular expression technology.

The Scan

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.

Breast Cancer Risk Gene Candidates Found by Multi-Ancestry Low-Frequency Variant Analysis

Researchers narrowed in on new and known risk gene candidates with variant profiles for almost 83,500 individuals with breast cancer and 59,199 unaffected controls in Genome Medicine.

Health-Related Quality of Life Gets Boost After Microbiome-Based Treatment for Recurrent C. Diff

A secondary analysis of Phase 3 clinical trial data in JAMA Network Open suggests an investigational oral microbiome-based drug may lead to enhanced quality of life measures.

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.